@RuellaLab

We focus on mechanisms of relapse after CAR-T therapy. Our goal is to design innovative combined IMT for relapsing/refractory Leukemia & Lymphoma. @MarcoRuella

 Philadelphia, PA
ruella-lab.framer.website/
Joined December 2019
  • Tweets57
  • Following50
  • Followers269
21Media
Harnessing the CD2 axis to broaden & enhance the efficacy of CAR T-cell therapies ft. @AlbertoCarturan, @Mat_Angelos & @MarcoRuella (@PennCancer) @RuellaLab @BloodPortfolio ashpublications.org/blood/ar…
4
10
443
CD2 is a viable target for CAR T-cell immunotherapy for T-cell malignancies, but CD2 deletion in CAR T cells can lead to dysfunction. Read in Blood: ow.ly/j41050YKAiI
8
21
1,574
New issue of Blood out now featuring Anti-CD2 CAR T-cells for T-cell neoplasms, Inflammatory landscape in clonal hematopoiesis, GRK5 variant linked to thrombotic disease, and more. Explore here: ashpublications.org/blood/is…
1
6
1
11
1,656
Ruella Lab retweeted
ASH
@ASH_hematologyMar 29
When political threats put scientific research at risk, your support of the ASH Foundation helped keep hematology vibrant and rewarding. Thank you for driving positive change in hematology. View the 2025 ASH Annual Report: ow.ly/2l5750YzTQT #Fight4Hematology
1
6
11
1,429
New research out @CellCellPress in finds that β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer ft. @Shan_Liu_ & @RuellaLab (@PennCancer) sciencedirect.com/science/ar…
1
6
22
1,341
Ruella Lab retweeted
Arc Institute
@arcinstituteMar 6
CAR T cell therapy has shown strong results against certain cancers, but metabolic exhaustion limits its effectiveness over time. In @CellCellPress, the @MaayanLevyPhD & @ChristophThaiss labs report that a common supplement can fuel CAR T cells to fight cancer more effectively.
2
44
1
167
13,472
Ruella Lab retweeted
Maayan Levy@MaayanLevyPhDMar 6
Excited to share our new paper in @CellCellPress with @MarcoRuella, led by @Shan_Liu_ and @PuneethGuru_. CAR T cell therapy loses effectiveness over time due to metabolic exhaustion, but we found a surprisingly simple approach to address it. 👇 cell.com/cell/abstract/S0092…
15
66
4
255
29,977
Ha distrutto le cellule tumorali presenti nei topi con la stessa efficacia ma senza attaccare anche quelle sane del sistema immunitario. E' la nuova terapia Car-T, che apre la strada verso futuri trattamenti senza effetti collaterali @Penn @MyUniSR ansa.it/canale_scienza/notiz…

Nuova terapia Car-T contro i tumori, non attacca le cellule sane - Biotech - Ansa.it

Lo indicano i test sui topi, verso futuri trattamenti senza effetti collaterali (ANSA)

ansa.it
1
6
296
A new design for #CARTcells that targets IGHV4-34 on B cell receptors can suppress lymphoma cells in vivo and neutralizes autoimmune #lupus B cells from patients, while avoiding off-target killing of healthy B cells. @MarcoRuella @PennCancer scim.ag/4azTURq
7
16
1,316
You know it's a big impact when Nature covers a Science journal paper. h/t Ivan J Cohen, Audrey C Bochi-Layec, @LemoineJean6 @MarcoRuella @PennMedicine @ScienceTM nature.com/articles/d41586-0…

Innovative CAR-T therapy destroys cancer cells without dangerous side effects

Nature - In mice, the treatment selectively targets tumour cells without suppressing the immune system.

nature.com
3
12
634
🚨NEW - Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells. 🧵below on why is this important. From Ivan J Cohen, Audrey C Bochi-Layec, @LemoineJean6 @MarcoRuella @PennMedicine @ScienceTM #TCell #CARTCell #immunotherapy science.org/doi/10.1126/scit…
1
8
1
32
2,177
An in-depth analysis of tissue biopsies from patients with multiple myeloma and CART-associated immune-related adverse events (CirAE) after treatment with commercial BCMA-CART shows that CD4+ CARTs mediate off tumor toxicities and that high CD4/CD8 ratio at apheresis, robust early CART expansion, ICANS, and cilta-cel treatment are independently associated with the development of CirAEs. nature.com/articles/s41591-0…
1
11
27
5,329
An in-depth analysis of tissue biopsies from patients with multiple myeloma and CART-associated immune-related adverse events (CirAE) after treatment with commercial BCMA-CART shows that CD4+ CARTs mediate off tumor toxicities and that high CD4/CD8 ratio at apheresis, robust early CART expansion, ICANS, and cilta-cel treatment are independently associated with the development of CirAEs. nature.com/articles/s41591-0…
1
10
33
4,904
New research finds that delayed toxicities after CAR T cell therapy for multiple myeloma are connected & potentially preventable ft. @JoeFraietta, @jh_noll (@PennMicro), @MarcoRuella, @CohenAd_MMdoc, Luca Paruzzo & @MatthewHoMD (@PennCancer) tinyurl.com/ysd4nsdh
4
7
635
Ruella Lab retweeted
LUMICKS
@LUMICKS_nl12 Dec 2025
CAR T therapy saves lives. But some myeloma patients develop serious delayed toxicities months later. At #ASH2025, Penn researchers led by Dr. @MarcoRuella revealed why: 👉 CD4⁺ CAR T cells show much stronger Cell Avidity to BCMA than CD8⁺ cells. This enhanced binding boosts tumor killing but also drives on-target, off-tumor toxicities in healthy tissues. Identifying Cell Avidity as the driver allowed the team to spot early warning signs and map a potential way to safely modulate CAR T activity. A major advance toward safer, next-generation CAR T therapies powered by a deeper understanding of Cell Avidity. 🔗Abstract of the research at #ASH2025: meetings-api.hematology.org/… 🔗Discover more Cell Avidity applications in cell therapy: lumicks.com/application/cell… 🔗Contact LUMICKS to implement Cell Avidity in your research: lumicks.com/contact
3
3
543
#ASH25 Seemingly disparate, delayed toxicities after BMCA CAR T for #multiplemyeloma share a common immune root cause and may be preventable, according to new research led by @jh_noll @MatthewHoMD @JoeFraietta @MarcoRuella @CohenAd_MMdoc. Learn more: spr.ly/60107h2Yp
7
1
15
1,356
.@puneeth_guru et al. @RuellaLab discuss the current landscape of single-cell transcriptomics for cancer #immunotherapy. bit.ly/3mslYtT From our Cancer Immunotherapy collection to accompany #SITC21 👉 bit.ly/3H5wvXl
6
16
Our letter to the @NEJM reporting the five-year outcomes of CART19 (CTL019, now called tisagenlecleucel) in lymphoma patients is out! Thanks to Drs. Schuster, Chong and @PennMedicine @PennCancer @Penn_IFI @carlhjune @BLLPHD nejm.org/doi/full/10.1056/NE…

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy | NEJM

Progression-free survival at 5 years was 31% in patients with diffuse large B-cell lymphoma and 43% in patients with follicular lymphoma. A total of 60% of patients remained in remission at 5 years...

nejm.org
4
30
1
128
Our latest review on single-cell RNAseq in immunotherapy is out in @JExpMed! Thanks for this Herculean endeavour to @puneeth_guru and @RuellaLab @PennMedicine @Penn_IFI – at Philadelphia, PA
Journal of Experimental Medicine@JExpMed18 Dec 2020
This review by @puneeth_guru, @MarcoRuella et al. @RuellaLab @PennMedicine examines how single-cell RNA sequencing has transformed the understanding of basic #cancer and immune biology in the context of cancer #immunotherapy. bit.ly/3mslYtT #JEMCancerFocus
14
1
62
This review by @puneeth_guru, @MarcoRuella et al. @RuellaLab @PennMedicine examines how single-cell RNA sequencing has transformed the understanding of basic #cancer and immune biology in the context of cancer #immunotherapy. bit.ly/3mslYtT #JEMCancerFocus
1
25
4
73
Load more